Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?

The absolute risk difference between GLP1RAs and placebo was not remarkable (5 -27/10,000 per year for different conditions such as biliary disease, cholelithiasis, cholecystitis, cholecystectomy and biliary cancer). In addition, the risk of pancreatitis was not higher (RR 1.46 [0.59 to 3.61], P val...

Unquestionably, GLP-1 RA therapy offers tremendous benefits for patients with type 2 DM, including improved cardiovascular outcomes. However, there are risks involved with the use of these medications. All of the currently available drugs in this class seem to carry an increased risk of cholelithias...